Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects With Advanced Solid Tumors and c-Met Dysregulation

Trial Profile

Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects With Advanced Solid Tumors and c-Met Dysregulation

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs CBT 101-Carlbiotech (Primary)
  • Indications Gastric cancer; Oesophageal cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors CBT Pharmaceuticals
  • Most Recent Events

    • 28 Sep 2017 According to a CBT Pharmaceuticals media release, first patient has been dosed.
    • 24 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 18 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top